Aleplasinin, formerly known as PAZ-417, is a selective inhibitor of PAI-1 under development for treatment of Alzheimer's disease. Plasminogen activator inhibitor-1 (PAI-1) is a key negative regulator of the fibrinolytic system. In animal studies, inhibition of PAI-1 activity prevents arterial and venous thrombosis, indicating that PAI-1 inhibitors may be used as a new class of antithrombotics. References:

纯度：≥98%

CAS：481629-87-2